Logo

FDA approves Watson ANDA

HealthSource Manager
  • About Us
  • Welcome New Pharmacy
  • News
  • Contact Us
  • Customer Login
  • Home

FDA approves Watson ANDA

Posted by HealthSource Manager on Monday, November 26, 2012

Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has won FDA approval for its abbreviated new drug application (ANDA) for Budesonide inhalation suspension 0.25mg/2mL and 0.5mg/2mL unit-dose ampoules.

Budesonide Inhalation Suspension is the generic equivalent to AstraZeneca's Pulmicort RESPULES, a maintenance medicine used to control and prevent asthma symptoms in children ages 12 months to eight years.

Watson considers launching the product in 2012 subject to obtaining a favorable outcome on an anticipated motion for a preliminary injunction in the pending litigation with AstraZeneca concerning the product.

Pulmicort RESPULES had total US sales of approximately $1.1bn according to IMS Health data, for the twelve months ending 31 May 2012.


▷ View more articles...

HealthSource Distributors, LLC

7200 Rutherford Rd . Suite 150 . Baltimore, MD 21244 . Phone: (855) 458-4772

Copyright (C) 2019 HealthSource Distributors, LLC